Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease

被引:10
作者
Rebecca Saich
Roger Chapman
机构
[1] The Department of Gastroenterology The John Radcliffe Hospital Headley Way Headington Oxford Oxfordshire OX3 9DU United Kingdom
[2] The Department of Gastroenterology The John Radcliffe Hospital Headley Way Headington Oxford Oxfordshire OX3 9DU United Kingdom
关键词
Primary sclerosing cholangitis; Autoimmune hepatitis; Liver disease; Inflammatory bowel disease; Crohns disease; Ulcerative colitis;
D O I
暂无
中图分类号
R574 [肠疾病]; R575.1 [肝炎];
学科分类号
1002 ; 100201 ;
摘要
Primary sclerosing cholangitis (PSC) is a chronic progressive disorder of unknown aetiology characterised by chronic inflammation and stricture formation of the biliary tree. Symptoms include itch and lethargy and in advanced cases cholangitis and end-stage liver disease, however increasing numbers of asymptomatic individuals are being identified. The disease is rare in the general population but is strongly associated with inflammatory bowel disease (IBD) affecting up to 5% of patients with Ulcerative Colitis, with a slightly lower prevalence (up to 3.6%) in Crohns disease. The strength of this association means that the vast majority (> 90%) of patients with PSC also have IBD, although many may have only mild gastro-intestinal symptoms. Usually IBD presents before PSC, although vice-versa can occur and the onset of both conditions can be separated in some cases by many years. Mean age of diagnosis of PSC is in the fifth decade of life with a strong male predominance. Risk is increased in those with a family history of PSC, suggesting a genetic predisposition and the disease is almost exclusive to non-smokers. The ulcerative colitis associated with PSC is characteristically mild, runs a quiescent course, is associated with rectal sparing, more severe right sided disease, backwash ilieitis and has a high risk of pouchitis post-colectomy. Most worrisome is the high risk of colorectal malignancy which necessitates routine colonoscopic surveillance. Cholangiocarcinoma is also a frequent complication of PSC with a 10%-15% lifetime risk of developing this condition. Treatment with high dose ursodeoxycholic acid offers some chemoprotective effects against colorectal malignancy and may decrease symptoms, biochemical and histological progression of liver disease. Small duct PSC patients characteristically have normal cholangiography, and liver biopsy is required for diagnosis, it appears to have a more favourable prognosis. Autoimmune Hepatitis(AIH) is also more prevalent in patients with IBD, with up to 16% of patients with AIH also having ulcerative colitis. A small subgroup of patients have a AIH- PSC overlap syndrome and the management of these patients depends on liver histology, serum IgM levels, autoantibodies, degree of biochemical cholestasis and cholangiography as some of these patients may respond to immunosupression.
引用
收藏
页码:331 / 337
页数:7
相关论文
共 38 条
[1]   The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis [J].
Levy, C ;
Lymp, J ;
Angulo, P ;
Gores, GJ ;
Larusso, N ;
Lindor, KD .
DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (09) :1734-1740
[2]   A pilot study of etanercept in the treatment of primary sclerosing cholangitis [J].
Epstein, MP ;
Kaplan, MM .
DIGESTIVE DISEASES AND SCIENCES, 2004, 49 (01) :1-4
[3]  
Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom[J] . Jeremy G.C Kingham,Narendra Kochar,Michael B Gravenor.Gastroenterology . 2004 (7)
[4]  
Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease[J] . J.Eaden.Alimentary Pharmacology & Therapeutics . 2003
[5]  
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a united states community[J] . Kiran Bambha,W.Ray Kim,Jayant Talwalkar,Heidi Torgerson,Joanne T Benson,Terry M Therneau,Edward V Loftus,Barbara P Yawn,E.Rolland Dickson,L.Joseph Melton.Gastroenterology . 2003 (5)
[6]   Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis [J].
Pardi, DS ;
Loftus, EV ;
Kremers, WK ;
Keach, J ;
Lindor, KD .
GASTROENTEROLOGY, 2003, 124 (04) :889-893
[7]   Outcome of patients undergoing liver transplantation for primary sclerosing cholangitis [J].
MacLean, AR ;
Lilly, L ;
Cohen, Z ;
O'Connor, B ;
McLeod, RS .
DISEASES OF THE COLON & RECTUM, 2003, 46 (08) :1124-1128
[8]   Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. [J].
Vera, A ;
Gunson, BK ;
Ussatoff, V ;
Nightingale, P ;
Candinas, D ;
Radley, S ;
Mayer, AD ;
Buckels, JAC ;
McMaster, P ;
Neuberger, J ;
Mirza, DF .
TRANSPLANTATION, 2003, 75 (12) :1983-1988
[9]  
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: A meta-analysis[J] . Roy M. Soetikno,Otto S. Lin,Paul A. Heidenreich,Harvey S. Young,Michael O. Blackstone.Gastrointestinal Endoscopy . 2002 (1)
[10]  
Small-duct primary sclerosing cholangitis: A long-term follow-up study[J] . Paul Angulo,Yaakov Maor-Kendler,Keith D. Lindor.Hepatology . 2002 (6)